PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan - Rising private expenditure, Ageing societies and increasing health awareness propel IVD market in Central and Eastern Europe - DrugDiscovery.Frost.com
IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/08/01 - Rising private expenditure, Ageing societies and increasing health awareness propel IVD market in Central and Eastern Europe - DrugDiscovery.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Scarcity of financial resources available for in vitro diagnostics (IVD) is the key challenge for the market across Central and Eastern Europe (CEE). At the same time, ageing societies, growing health awareness and increasing affluence are boosting demand for IVD testing, including technologically advanced molecular diagnostic testing.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Strategic Analysis of CEE IVD Market, finds that the market earned revenues of $991.4 million in 2010 and estimates this to reach $1,880.2 million in 2017. The study covers clinical chemistry, hematology, microbiology, point-of-care testing, self-monitoring of blood glucose, molecular diagnostics and immunodiagnostics products in the Czech Republic, Hungary, Poland and Russia.

"The rising demand for private testing is a result of the poor efficiency and quality of public laboratories as well as insufficient public funding for IVD in the CEE region," notes Frost & Sullivan Research Analyst Dominika Grzywinska. "This factor is especially visible in Russia, where paid diagnostic services are booming."

In Russia, receiving services financed by the compulsory health insurance (OMS) is very difficult. Public laboratories face several problems, such as poor quality of service, insufficient supply of diagnostic equipment and long waiting times. In other CEE countries, the key reason for people opting for private testing is insufficient financing from health insurance.

Financial resources available for IVD services are insufficient. The money spent on IVD in CEE countries constituted between 1 and 2 per cent of total healthcare expenditure in 2010.

In the Czech Republic, healthcare funding is being reduced, which has limited the resources for IVD. In Poland, there is an absence of control mechanisms on how much should be spent on IVD. In Russia, limited financing has resulted in long waiting lines and poor quality of publicly provisioned laboratory diagnostic services. In Hungary, volume limits were introduced for laboratory services financing in 2006.

"Increasing affluence in these countries, coupled with growing health awareness has, therefore, resulted in higher private expenditure on laboratory diagnostics," remarks Grzywinska.

The lack of funding for IVD has resulted in slow technology uptake and high price sensitivity across CEE. Another challenge relates to the high fragmentation of laboratories, which decreases their efficiency.

Research shows that countries in CEE do not fall behind the developed countries in terms of technologies. New solutions are introduced practically at the same time as in western countries.

"The key difference between those two regions is that the commercial uptake of technologies is much slower in CEE, due to the scarcity of financial resources available for IVD," elaborates Grzywinska. "As a result, even though a technology is available in the country, it may still not be used in routine testing and not be reimbursed."

Furthermore, low public expenditure on IVD has led to increasing price pressures. Price remains the key decision-making factor for end users and this situation is likely to persist throughout 2011-2017.

End users of the CEE IVD market are predominantly small laboratories performing a low number of tests annually. They do not purchase large amounts of reagents, and therefore have to pay retail prices, instead of lower, wholesale prices. In this case, one dollar spent on diagnostics in CEE is less efficient than one dollar spent on diagnostics in western European countries.

"Although new technologies are present in the CEE countries, lack of funding inhibits their commercialisation," states Grzywinska. "Delivering product of top quality at affordable prices is the key to achieving success."

Increasing public financing for IVD would be the fastest and most effective means to improve market prospects. However, in the face of cost mitigation efforts undertaken by governments, this scenario seems unlikely. Therefore, manufacturers should be aware of end users' high price sensitivity and try to balance product performance with cost.

If you are interested in more information on this study, please send an email with your contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]frost.com.

Strategic Analysis of CEE IVD Market is part of the Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: Eastern European IVD Market, Western European IVD Markets and Strategic Analysis of the Global In Vitro Diagnostics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Strategic Analysis of CEE IVD Market / M693

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Janique Morvan 
+33 (0)1 42 81 20 37 janique.morvan[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)